Research & Development
Cutting Edge Laser Technologies publishes case report in American Journal of Case Reports of Supportive Photobiomodulation Therapy in COVID-19 patients
10 August 2020 -

Cutting Edge Laser Technologies said on Sunday that its principal investigator and lead author Dr Scott Sigman has announced positive results from the first-ever use of laser therapy (PBMT) to treat a COVID-19 pneumonia patient at the Massachusetts Hospital.

In Photobiomodulation Therapy (PBMT), the light is applied over damaged tissues of the COVID patient and light energy is absorbed by cells starting a cascade of molecular reactions that improve cell function and enhance the body's healing process. PBMT has demonstrated anti-inflammatory effects and is emerging as an alternative modality in pain management, lymphedema treatment, wound healing and musculoskeletal injuries.

The company added that the 57-year-old African American patient, who is part of a randomized clinical pilot trial involving ten patients with confirmed COVID-19, was diagnosed with SARS-CoV-2, and admitted to the ICU for respiratory distress and in need of oxygenation. He was treated with once-daily, 28-minute PBMT sessions for four days using an FDA-cleared Multiwave Locked System (MLS) Therapy Laser.



Related Headlines